Replimune Group, Inc. — Director's Dealing 2021

Apr 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Replimune Group, Inc. (REPL)
CIK: 0001737953
Period of Report: 2021-04-01

Reporting Person: Rhodes Jason P (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-01	Stock Option (right to buy)	$31.58	A	16500	Acquired	2031-04-01	Common Stock (16500)	Direct

Footnotes

F1: This option was granted on April 1, 2021 with respect to 16,500 shares of the Issuer's common stock and vests in full on April 1, 2022.

F2: The Reporting Person is a member of Atlas Venture Associates X, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the option to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.